CAMP4 Therapeutics has received Australian regulatory and ethics clearance to [...]

Enterome Phase 1/2 data show EO2463-induced CD8 T-cell expansion was [...]

Telix has dosed the first patient in a Phase 3 [...]

Medicus Pharma has received positive feedback from FDA and central [...]

Skyhawk Therapeutics has expanded its global pivotal Phase 2/3 clinical [...]

Q32 Bio has reported positive 36-week Phase 2 data showing [...]

Poolbeg Pharma has dosed the first patient in a clinical [...]

FORE Biotherapeutics has completed target enrolment in the primary central [...]

Compass Pathways has reported positive six-month results from its second [...]

EnteroBiotix has dosed the first patient in its Phase 2b [...]